Wakefit IPO Day 1: Check Subscription Status, Key Highlights, and More

08 December 2025
1 min read
whatsapp
facebook
copyToClipboard

India’s largest D2C home and furnishings company, Wakefit, has launched its Initial Public Offering (IPO) for public subscription today, December 8, 2025. Prior to the IPO opening, the company raised ₹580 crore from anchor investors on December 5, 2025. 

Wakefit IPO: Issue Details

The Wakefit IPO is a book-building issue of ₹1,288.89 crore, consisting of a fresh issue of ₹377.18 crore and an offer for sale (OFS) of ₹911.71 crore.   

The price band is set between ₹185 and ₹195 per share. The basis of allotment will be finalised by December 11, 2025, and the tentative listing date on BSE and NSE is December 15, 2025. 

Wakefit IPO Day 1 Subscription Status

[8-December-2025 10:57:00 hrs]

Investor Category

Subscription (Times)

Qualified Institutional Buyers (QIBs)

0.00

Non-Institutional Investors

0.03

Retail Individual Investors (RIIs)

0.27

Total

0.06

Utilisation of IPO Proceeds

  • The net proceeds from the fresh issue will be used to fund capital expenditure towards 
    • Setting up of 117 new COCO – Regular Stores 
    • Lease, sub-lease, rent and licence fee payments for existing COCO – Regular Stores
    • Purchase of new equipment and machinery
    • Marketing and advertisement expenses
  • General corporate purposes

Wakefit Business Overview

Wakefit is one of India’s leading direct-to-consumer (D2C) home and sleep solutions companies. With a vertically integrated model, the company manages the entire value chain end-to-end, from research and product conceptualisation to design, engineering, manufacturing, distribution, and post-purchase customer experience. 

Their product portfolio includes mattresses, furniture, furnishings, and home improvement products. The company’s revenue from operations has grown at a CAGR of 24.87% from FY 2022 to FY 2024. 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here.

Do you like this edition?